Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;25(2):177-184.
doi: 10.1007/s10787-017-0333-4. Epub 2017 Mar 7.

Update on biosimilars in rheumatology

Adam Rischin  1 , Andrew J K Östör  2
Affiliations
Review

Update on biosimilars in rheumatology

Adam Rischin et al. Inflammopharmacology. 2017 Apr.

Abstract

Biologic agents have become indispensable in the management of autoimmune disease particularly rheumatological conditions. The lives of countless individuals have been improved following treatment with these drugs. Unfortunately, their cost prohibits more widespread use around the globe. This critical issue has been addressed by the introduction of biosimilars into the market. These therapies have been developed to resemble the originator molecule as closely as possible and to increase competition in the therapy area thus allowing costs to be reduced. Our review is intended to offer an update on biosimilars including logistic considerations on their introduction into routine practice.

Keywords: Biologics; Biosimilars; Efficacy; Health economics; Logistics; Rheumatology; Safety.

PubMed Disclaimer

References

    1. Lancet. 1999 Dec 4;354(9194):1932-9 - PubMed
    1. Arthritis Care Res (Hoboken). 2012 Nov;64(11):1649-56 - PubMed
    1. Nat Rev Rheumatol. 2015 Dec;11(12):713-24 - PubMed
    1. J Med Chem. 2010 Dec 23;53(24):8468-84 - PubMed
    1. Expert Rev Clin Immunol. 2014 Aug;10(8):981-3 - PubMed

Substances

LinkOut - more resources